Journal
CURRENT OPINION IN ONCOLOGY
Volume 20, Issue 2, Pages 206-219Publisher
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/CCO.0b013e3282f5123d
Keywords
FDG PET; Hodgkin's lymphoma; non-Hodgkin's lymphoma; prognosis; transplantation
Categories
Funding
- NCI NIH HHS [K23 CA124465-01A2, K23 CA124465] Funding Source: Medline
- NATIONAL CANCER INSTITUTE [K23CA124465] Funding Source: NIH RePORTER
Ask authors/readers for more resources
Purpose of review The prognostic utility of midtreatment fluorine-18 fluorodeoxyglucose positron emission tomography (F-18-FDG PET) has become widely appreciated in aggressive B-cell non-Hodgkin's lymphoma and, more recently, in Hodgkin's lymphoma. Outcomes based on midtreatment FDG PET performed during primary and salvage therapy are reviewed and management strategies considered, with a focus on treatment intensification for poor-risk disease as identified by metabolic imaging. Recent findings PET, when performed after as few as two cycles of primary chemotherapy, is strongly prognostic in certain aggressive lymphomas and provides information independently from validated prognostic indices. What constitutes a positive or negative scan is not always clear, particularly if there is minimal tracer uptake, and the causes of false positive and false negative scans must be considered. How to tailor therapy based on the midtreatment PET result is the focus of current trials and is presently being defined for both Hodgkin's and non-Hodgkin's lymphoma. Summary Early PET has the strong potential to improve clinical outcomes by sparing good-risk patients from overly aggressive treatments, and by more accurately identifying poor-risk patients so as to guide changes in management. Treatment modifications on the basis of midtreatment PET are presently best made in clinical trial settings.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available